Niche CKD unmet Tricida focuses on veverimer for metabolic acidosis in chronic kidney disease, presenting a specialized, high-need indication that can drive targeted outreach to nephrology and CKD management teams with limited competing therapies.

Early-stage commercial With a small team and modest revenue, there is an opportunity to partner with larger pharma or contract organizations to scale manufacturing, distribution, and commercialization efforts while leveraging Tricida’s technical expertise in polymer-based kidney therapies.

Regulatory risk Historical securities-related challenges and ongoing fiduciary investigations suggest heightened risk disclosure needs; BD discussions should include robust risk management, regulatory compliance diligence, and transparent governance assurances when engaging potential investors or partners.

Strategic partnerships Given limited headcount and specific CKD focus, align with academic centers, nephrology networks, payer collaboratives, and contract development and manufacturing organizations to expand clinical access, reimbursement pathways, and market penetration efficiently.

Market signaling Revenue in the tens of millions range positions Tricida as a potential acquisition or out-licensing candidate for larger biotech firms seeking to diversify kidney disease portfolios, especially those looking to augment polymer-based therapeutic platforms.